Overview Denosumab China Phase III Study Status: Completed Trial end date: 2015-08-01 Target enrollment: Participant gender: Summary This study is to evaluate the efficacy and safety of denosumab 60 milligrams (mg) for 12 month treatment in Chinese postmenopausal women with osteoporosis at increased risk of fracture. Phase: Phase 3 Details Lead Sponsor: GlaxoSmithKlineTreatments: CalciumDenosumabVitamin D